FY2028 Earnings Estimate for Merus Issued By William Blair

Merus (NASDAQ:MRUS - Free Report) - Analysts at William Blair issued their FY2028 earnings per share (EPS) estimates for shares of Merus in a note issued to investors on Friday, February 28th. William Blair analyst M. Phipps expects that the biotechnology company will post earnings of ($3.58) per share for the year. William Blair has a "Outperform" rating on the stock. The consensus estimate for Merus' current full-year earnings is ($3.85) per share.

A number of other analysts have also recently commented on MRUS. Piper Sandler initiated coverage on Merus in a research report on Thursday, February 13th. They set an "overweight" rating and a $84.00 price objective for the company. The Goldman Sachs Group began coverage on shares of Merus in a research report on Thursday, November 21st. They set a "buy" rating and a $73.00 price target for the company. Guggenheim restated a "buy" rating on shares of Merus in a research report on Wednesday, February 12th. HC Wainwright reiterated a "buy" rating and issued a $85.00 price target on shares of Merus in a research report on Monday. Finally, Citigroup upped their price objective on Merus from $89.00 to $97.00 and gave the stock a "buy" rating in a research note on Monday, December 9th. One investment analyst has rated the stock with a sell rating, fourteen have issued a buy rating and two have assigned a strong buy rating to the company's stock. According to data from MarketBeat.com, the company presently has an average rating of "Buy" and a consensus target price of $85.77.

Remove Ads

Merus Stock Performance

Shares of NASDAQ MRUS traded up $0.42 during midday trading on Monday, hitting $46.71. 185,186 shares of the stock traded hands, compared to its average volume of 632,212. The firm has a market capitalization of $3.20 billion, a P/E ratio of -11.80 and a beta of 1.11. Merus has a one year low of $37.77 and a one year high of $61.61. The firm has a 50-day moving average of $42.22 and a two-hundred day moving average of $46.65.

Merus (NASDAQ:MRUS - Get Free Report) last issued its earnings results on Thursday, February 27th. The biotechnology company reported ($0.41) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.89) by $0.48. Merus had a negative net margin of 680.61% and a negative return on equity of 38.89%. The company had revenue of $9.14 million for the quarter, compared to analysts' expectations of $10.57 million.

Hedge Funds Weigh In On Merus

A number of hedge funds have recently made changes to their positions in the business. Mirae Asset Global Investments Co. Ltd. lifted its holdings in Merus by 24.7% in the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,467 shares of the biotechnology company's stock worth $118,000 after purchasing an additional 489 shares in the last quarter. abrdn plc bought a new position in shares of Merus during the third quarter worth $4,357,000. US Bancorp DE purchased a new position in Merus during the third quarter valued at $103,000. Harbor Capital Advisors Inc. purchased a new position in Merus during the third quarter valued at $2,113,000. Finally, TimesSquare Capital Management LLC increased its holdings in Merus by 49.5% in the 3rd quarter. TimesSquare Capital Management LLC now owns 272,435 shares of the biotechnology company's stock valued at $13,611,000 after acquiring an additional 90,215 shares during the last quarter. Institutional investors own 96.14% of the company's stock.

About Merus

Merus N.V., a clinical-stage immuno-oncology company, engages in the development of antibody therapeutics in the Netherlands. Its bispecific antibody candidate pipeline includes Zenocutuzumab (MCLA-128), which is in a phase 2 clinical trials for the treatment of patients with metastatic breast cancer and castration-resistant prostate cancer, as well as in Phase 1/2 clinical trials for the treatment of solid tumors that harbor Neuregulin 1.